We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




3D Model Could Enable Earlier Detection of Esophageal Cancer

By HospiMedica staff writers
Posted on 19 Nov 2007
A new model of esophageal cancer holds promise as an experimental platform to investigate the etiology and possible treatment of this devastating disease. More...


There are two main types of esophageal cancer: squamous cell carcinoma and adenocarcinoma. Esophageal squamous cell carcinoma (ESCC) is the third most common cancer of the digestive tract and the seventh leading cause of cancer-related deaths worldwide. It is a highly malignant cancer and generally carries a poor prognosis, owing to its predominantly late detection.

A team of scientists from the University of Pennsylvania (Philadelphia, PA, USA), led by Dr. Anil Rustgi, developed the new model of ESCC. "This model allows us to dissect the specific genetic alterations that are important in the initiation and progression of esophageal squamous cell cancer, which holds promise for squamous cell cancers arising in other sites, such as the skin, lung, head, and neck,” explained Dr. Rustgi.

Dr. Rustgi and colleagues developed a tissue-engineered, organotypic three-dimensional (3D) culture system of esophageal squamous cell cancer. They found that ESCC results from a combination of genetic mutations (namely, epidermal growth factor receptor [EGFR] overexpression, hTERT activation, and p53 mutation), as well as changes in the tumor microenvironment.

Dr. Rustgi emphasized, "we have found that altering the stromal fibroblasts can influence the extent of tumor cell migration and invasion. Thus, previously underappreciated, it is the interplay of tumor cells and fibroblasts that has great meaning on how cancer arises and progresses.”

The model was described in the November 1, 2007, issue of the journal Genes and Development.


Related Links:
University of Pennsylvania

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical Examination & Procedure Light
Vega 80
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.